Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesCoeptis Therapeutics Inc

Coeptis Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None USD 0.00(0%)
Last update at 2026-05-28T22:01:19.295194Z
Market Cap
92.91M

Momentum Score

…

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical and technology company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its therapeutic portfolio includes an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. The company's product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; CD38-Diagnostic, an in vitro screening tool to analyze cancer patients if cancer patients might be appropriate candidates for anti-CD38 mAb therapy; and SNAP-CAR, a chimeric antigen receptor (CAR) therapy for treatment for cancer. In addition, the company offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
6.26
Low
21.41
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
1.36M
Revenue Per Share
0.32
Gross Profit TTM
1.18M
Debt / Equity
0.02
ROE
-136.91%
Net Debt
-5.41M
ROCE
-72.17%
Diluted EPS TTM
-2.81

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -12.28M -10.88M -21.27M -37.57M -13.45M
Minority interest 0.36M 1.06M 0.00M - -
Net income -11.92M -10.88M -21.27M -40.97M -14.42M
Selling general administrative 1.15M 0.95M 3.95M 34.17M 14.12M
Selling and marketing expenses 0.10M 0.01M 0.01M 0.01M 0.00M
Gross profit -2.83M -1.04M -1.00M 0.00M 0.07M
Reconciled depreciation 1.22M 1.04M 1.00M 1.00M 0.45M
Ebit -13.04M -10.48M -21.16M -34.20M -14.05M
Ebitda -11.82M -9.44M -20.16M -32.96M -12.81M
Depreciation and amortization 1.22M 1.04M 1.00M 1.24M 1.23M
Operating income -13.04M -10.05M -21.49M -34.20M -14.05M
Other operating expenses 14.41M 10.05M 21.49M 34.20M 14.12M
Interest expense 0.64M 0.40M 0.11M 0.22M 0.19M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 0.12M 0.23M - - -
Net interest income -0.53M -0.40M -0.14M -0.22M -0.19M
Income tax expense -0.36M -1.06M 3.39M 3.39M 0.97M
Total revenue 1.36M 0.00M 0.00M 0.00M 0.07M
Total operating expenses 14.23M 9.02M 20.49M 34.20M 14.12M
Cost of revenue 4.20M 1.04M 1.00M 0.00M 0.96M
Total other income expense net 0.77M -0.82M 0.22M -3.38M 0.60M
Net income from continuing ops -12.28M -10.88M -20.19M -37.57M -13.45M
Net income applicable to common shares - - - -37.57M -13.45M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 19.84M 8.91M 8.07M 7.92M 6.77M
Intangible assets 0.36M 0.54M - - -
Other current assets 0.99M 0.52M 0.24M 0.14M -
Total liab 2.09M 5.04M 3.76M 3.11M 4.41M
Total stockholder equity 17.25M 3.19M 4.31M 4.80M 2.35M
Other current liab 0.16M 2.01M 0.56M 0.18M 0.20M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -109.95M -98.23M -87.36M -65.74M -27.55M
Other assets - - - 3.90M 0.00M
Cash 5.67M 0.53M 1.47M 3.79M 2.18M
Total current liabilities 1.77M 4.51M 2.99M 1.82M 2.76M
Current deferred revenue 0.60M - - - 1.00M
Net debt -5.41M 0.87M -0.24M -2.08M 1.90M
Short term debt 0.12M 1.23M 1.01M 1.54M 2.43M
Short long term debt 0.10M 1.19M 0.97M 1.50M 2.42M
Short long term debt total 0.27M 1.40M 1.22M 1.71M 4.08M
Other stockholder equity 127.20M 101.42M 91.67M 70.54M 29.90M
Property plant equipment - - - - 0.03M
Total current assets 7.35M 1.05M 5.25M 3.94M 2.18M
Long term investments 7.86M 5.69M - - -
Net tangible assets - - - 4.80M 2.35M
Short term investments 0.68M 0.00M - - -
Net receivables 0.01M 0.04M 3.54M 0.01M 0.02M
Long term debt 0.15M 0.15M 0.15M 0.15M 1.65M
Inventory - - - - 0.00M
Accounts payable 0.89M 1.27M 1.42M 0.10M 0.13M
Non currrent assets other 4.25M 1.56M 2.71M 3.90M 4.55M
Non current assets total 12.49M 7.86M 2.82M 3.97M 4.59M
Capital lease obligations 0.02M 0.06M 0.10M 0.06M 0.01M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 0.00M 0.00M 0.00M -1.75M
Change to liabilities - - - -0.04M -2.58M
Total cashflows from investing activities - - - - -1.75M
Net borrowings 0.77M 1.20M -0.57M - -1.62M
Total cash from financing activities 13.74M 5.71M 5.49M 5.49M 8.22M
Change to operating activities - - - -0.51M -0.42M
Net income -11.92M -10.88M -37.57M -37.57M -13.45M
Change in cash 5.14M -0.94M 1.61M 1.61M 1.98M
Begin period cash flow 0.53M 1.47M 2.18M 2.18M 0.20M
End period cash flow 5.67M 0.53M 3.79M 3.79M 2.18M
Total cash from operating activities -8.60M -6.65M -3.88M -3.88M -4.49M
Issuance of capital stock 12.97M 4.01M 3.54M 3.27M 10.14M
Depreciation 1.22M 1.04M 1.00M 1.00M 0.45M
Dividends paid - - - - 0.08M
Change to inventory - - - - -0.42M
Change to account receivables -0.01M -0.23M -0.01M -0.01M 0.02M
Sale purchase of stock - - - 0.00M -0.25M
Other cashflows from financing activities - 4.41M 4.63M 4.63M 0.10M
Change to netincome - - - - 11.49M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 1.75M
Change in working capital -1.46M -0.13M -0.55M -0.55M -2.98M
Stock based compensation 1.22M 1.10M 0.48M 0.00M 1.90M
Other non cash items 2.34M 2.21M 33.25M 33.25M 4.26M
Free cash flow -8.60M -6.65M -3.88M -3.88M -6.24M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Coeptis Therapeutics Inc

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical and technology company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its therapeutic portfolio includes an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. The company's product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; CD38-Diagnostic, an in vitro screening tool to analyze cancer patients if cancer patients might be appropriate candidates for anti-CD38 mAb therapy; and SNAP-CAR, a chimeric antigen receptor (CAR) therapy for treatment for cancer. In addition, the company offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

105 Bradford Rd, Wexford, PA, United States, 15090

(724) 934-6467

https://coeptistx.com

4

Name Title Year Born
Mr. David Mehalick Co-Founder, Chairman, CEO & Pres 1969
Ms. Christine Elise Sheehy Co-Founder, CFO & Sec. 1967
Mr. Daniel Alexander Yerace Co-Founder, VP of Operations & Director 1983
Mr. Gary R. Conte Sr. VP of Sales & Marketing NA
Mr. David Mehalick Co-Founder, Chairman of the Board, CEO & President 1969
Ms. Christine Elise Sheehy Co-Founder and VP of Compliance & Corporate Secretary 1968
Mr. Brian Cogley M.B.A. Chief Financial Officer 1987
Dr. Colleen Delaney M.D., M.Sc. CSO & Chief Medical Officer 1968
Ms. Christine Elise Sheehy Co-Founder, VP of Compliance & Corporate Secretary 1968

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…